Crescita Therapeutics (CTX) Q3 2025 earnings summary

Executive summary

• Q3-2025 revenue rose to $5,393, up $1,799 year-over-year, driven by strong Manufacturing segment performance and new client volumes.

• Net income reached $753, reversing a net loss of $(1,036) in Q3-2024; adjusted EBITDA improved to $262 from $(681).

• Acquisition of Laboratoire Provence-Canada Inc. assets and a new five-year supply agreement expanded recurring revenue and manufacturing capacity.

Financial highlights

• Gross profit increased to $2,855 from $1,967 year-over-year; gross margin was 52.9% versus 54.7%.

• Operating expenses decreased to $3,017 from $3,139; operating loss narrowed to $(162) from $(1,172).

• Cash and cash equivalents ended at $8,308, up $124 for the quarter.

• Cash provided by operating activities was $1,173 for the quarter.

Outlook and guidance

• Integration of acquired assets and new supply agreement expected to bolster recurring revenue and plant utilization.

• Management continues to seek new partnerships for Pliaglis in regained territories.